Supplementary Information

Hepatic Forkhead Box Protein A3 regulates ApoA-I expression, cholesterol efflux and atherogenesis

Yuanyuan Li^{1*}, Yanyong Xu^{1*}, Kavita Jadhav¹, Yingdong Zhu¹, Liya Yin¹, and Yanqiao Zhang^{1**}

¹Department of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, OH, USA 44272

* Contributed equally to this work.



Supplementary Figure I. Fatty acids reduce FOXA3 protein expression in primary hepatocytes. A and B, Mouse primary hepatocytes were treated with various concentrations of palmitate (A) or oleic acid (B) for 24 h. MTT assays were performed to determine cell viability. C and D, Mouse primary hepatocytes were treated with 250 μ M palmitate acid (C) or oleic acid (D) for 16 hours, followed by western blot analysis. E, Proteins levels in C or D were quantified. * *P*<0.05, ** *P*<0.01



Supplementary Figure II. Plasma biochemistry, hepatic cholesterol levels, and hepatic mRNA levels in mice over-expressing FOXA3. C57BL/6J mice were i.v. injected with Ad-Empty or Ad-hFOXA3. Mice were sacrificed 7 days later (n=8 per group). A, Plasma ALT and AST levels. B, Plasma cortisol levels. C, Plasma testosterone levels. D, Plasma glucose levels. E, Hepatic total cholesterol levels. F and G, Hepatic mRNA levels. * P<0.05, ** P<0.01



Supplementary Figure III. Plasma biochemistry, hepatic cholesterol levels, and hepatic mRNA levels in mice with deficiency in hepatic Foxa3. C57BL/6J mice were i.v. injected with Ad-shLacZ or Ad-shFoxa3 (n=8 per group). Mice were sacrificed 7 days later. A, Plasma cortisol levels. B, Plasma testosterone levels. C, Plasma glucose levels. D, Hepatic cholesterol levels. E-G, Hepatic mRNA levels. * P < 0.05. ** P < 0.01



Supplementary Figure IV. Knockdown of *Foxa3* reduces *Apoa1* and *Pon1* expression in primary hepatocytes. Mouse primary hepatocytes were infected with Ad-shLacZ or Ad-shFoxa3 for 24 h. A, Cell viability was determined by MTT assays when primary hepatocytes were infected with adenoviruses at an MOI of 0, 5 or 10 (n=7). B, mRNA levels were determined in primary hepatocytes infected with adenoviruses at an MOI of 10. * P < 0.05. ** P < 0.01



Supplementary Figure V. FOXA3 over-expression or knockdown does not affect liver proliferation in adult mice. A-D, C57BL/6J mice were i.v. injected with Ad-Empty, Ad-hFOXA3 (A, C), Ad-shLacZ or Ad-shFoxa3 (B, D) (n=8 per group). After 7 days, livers were collected. Liver sections were immunostained with a Ki-67 antibody (A, B). Hepatic mRNA levels were determined (C, D). Arrows indicate Ki-67 staining-positive cells.



Supplementary Figure VI. Effect of hepatic FOXA3 over-expression in female mice. C57BL/6J mice were i.v. injected with Ad-Empty or Ad-hFOXA3 (n=6 per group). After 7 days, mice were euthanized. **A**, Plasma cholesterol levels. **B**, Plasma TG and glucose levels. Glucose levels were determined after a 12-h fast. **C**, Hepatic mRNA levels. **D**, Intestinal *Apoa1* mRNA levels. * *P*<0.05. ** *P*<0.01



Supplementary Figure VII. Effect of hepatic FOXA3 knockdown in female mice. C57BL/6J mice were i.v. injected with Ad-shLacZ or Ad-shFoxa3 (n=6 per group). After 7 days, mice were euthanized. **A**, Plasma cholesterol levels. **B**, Plasma TG and glucose levels. Glucose levels were determined after a 12-h fast. **C**, Hepatic mRNA levels. **D**, Intestinal *Apoa1* mRNA levels. * *P*<0.05. ** *P*<0.01



Supplementary Figure VIII. Hepatocyte-specific over-expression of FOXA3 lowers body fat but does not affect plasma total cholesterol or triglyceride levels. $Apoe^{-/-}$ mice were i.v. injected with AAV8-ALB-Null or AAV8-ALB-FOXA3 and then fed a Western diet for 3 months (n=8 per group). A, Body fat content was determined by Echo-MRI. No change in food intake was observed. B, Plasma total cholesterol (chol) levels. C, Plasma triglyceride (TG) levels. D, Plasma glucose levels. E, Plasma ALT and AST levels. F, Plasma cortisol levels. G, Plasma testosterone levels. H, Hepatic mRNA levels. * P<0.05, ** P<0.01